SABCS: Acupuncture Relieves AI-Linked Joint Pain in Breast CA

Share this content:
SABCS: Acupuncture Relieves AI-Linked Joint Pain in Breast CA
SABCS: Acupuncture Relieves AI-Linked Joint Pain in Breast CA

THURSDAY, Dec. 7, 2017 (HealthDay News) -- Acupuncture is associated with improvements in joint pain for patients with early-stage breast cancer (BC) taking aromatase inhibitors, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 5 to 9 in Texas.

Dawn L. Hershman, M.D., from the Herbert Irving Comprehensive Cancer Center at the NewYork-Presbyterian/Columbia University Medical Center in New York City, and colleagues randomized postmenopausal women with early-stage BC who were taking an aromatase inhibitor for ≥30 days and with a worst pain score of ≥3 out of 10 using the Brief Pain Inventory (BPI) to true acupuncture (TA; 110 patients), sham acupuncture (SA; 59 patients), and waitlist control (WC; 57 patients).

The researchers found that the six-week mean BPI worst pain scores were 0.92 points lower in the TA versus SA arm, and 0.96 points lower in the TA versus WC arm. The proportion of patients experiencing a clinically meaningful reduction in BPI worst pain was 58, 33, and 31 percent for TA, SA, and WC, respectively. Improved symptoms were seen for patients randomized to TA versus SA at week six in all BPI pain measures (average pain, pain interference, pain severity, worst stiffness); similar results were seen compared with WC. Significant or marginally significant improvements in BPI pain measures were also seen at week 12 for TA.

"We were very pleased to see acupuncture had durable beneficial effects with no significant side effects in a large, rigorous clinical trial," Hershman said in a statement.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »